CredoScientia - Bibliothèque

Anlotinib plus envafolimab as neoadjuvant therapy in a patient with chemotherapy-refractory advanced endometrial cancer: A case report. New

We report a case of a 51-y-old female presenting with synchronous double primary malignancies: advanced endometrial cancer and early-stage lung cancer. One year a post-chemotherapy withdrawal due to t…

Thérapies de Conversion

Xu, J., Zhuang, D., Wang, L., Dong, L., Sun, Y., & Xiao, W. (2026). Anlotinib plus envafolimab as neoadjuvant therapy in a patient with chemotherapy-refractory advanced endometrial cancer: A case report.. Hum Vaccin Immunother, 22(1), 2664297. https://doi.org/10.1080/21645515.2026.2664297

01/12/2026 Lire →

Cognitive-behavioral treatment of gender dysphoria in youth: Opportunities, challenges, and responsibilities. New

During the past twenty years, the prevailing clinical approach to child and adolescent gender dysphoria changed dramatically. Before then, most clinicians considered youth gender dysphoria a mental he…

Thérapies de Conversion

Bailey, J. M., & Zucker, K. J. (2026). Cognitive-behavioral treatment of gender dysphoria in youth: Opportunities, challenges, and responsibilities.. Curr Opin Psychol, 70, 102323. https://doi.org/10.1016/j.copsyc.2026.102323

01/08/2026 Lire →

The influence of politics on psychological interventions for pediatric gender dysphoria. New

The care of children and youth presenting with gender dysphoria has recently changed from watchful waiting and psychotherapeutic exploration to primarily an affirmative medical pathway involving socia…

Thérapies de Conversion

Mason, J. W., Grignon, P., & Cohn, J. (2026). The influence of politics on psychological interventions for pediatric gender dysphoria.. Curr Opin Psychol, 70, 102314. https://doi.org/10.1016/j.copsyc.2026.102314

01/08/2026 Lire →

Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC.

BACKGROUND & AIMS: Transarterial chemoembolization (TACE) combined with targeted therapy and immunotherapy is a promising approach for intermediate and advanced hepatocellular carcinoma (HCC). This st…

Thérapies de Conversion

Tang, S., Yan, X., Gong, T., Zhi, W., Gao, Y., & Han, Y. (2026). Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC.. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-026-06541-6

13/06/2026 Lire →

Resectability redefined: Lessons from quadruple therapy in HCC.

Qiu et al. report a phase II trial (PLATIC) evaluating sintilimab, lenvatinib, and transarterial chemoembolization combined with hepatic arterial infusion chemotherapy (TACE-HAIC) as conversion therap…

Thérapies de Conversion

Jiang, N., & Zhong, B. Y. (2026). Resectability redefined: Lessons from quadruple therapy in HCC.. Med, 7(6), 101136. https://doi.org/10.1016/j.medj.2026.101136

12/06/2026 Lire →

Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial.

BACKGROUND: Transarterial chemoembolization (TACE) or systemic treatments are recommended for unresectable hepatocellular carcinoma (uHCC) but have low conversion-to-resection rates. This single-arm p…

Thérapies de Conversion

Qiu, J., Huang, Z., He, W., Wang, C., Xie, C., Shen, J., Cai, M., Yuan, Y., Zou, R., Li, B., & Yuan, Y. (2026). Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial.. Med, 7(6), 101132. https://doi.org/10.1016/j.medj.2026.101132

12/06/2026 Lire →

Low-Dose SBRT-Based Radiotherapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable NSCLC: A Phase Ib Study.

PURPOSE: Chemoradiotherapy is standard for unresectable stage III non-small cell lung cancer (NSCLC). This phase Ib study assessed the safety and surgical conversion of neoadjuvant low-dose stereotact…

Thérapies de Conversion

Zhu, X., Zhao, L., Zhang, S., Guo, H., Jiang, N., Zhang, H., Jiang, F., Ding, N., Ren, B., & Li, M. (2026). Low-Dose SBRT-Based Radiotherapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable NSCLC: A Phase Ib Study.. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2026.05.055

09/06/2026 Lire →

Immune Related Pathological Features and Predictive Score in Intrahepatic Cholangiocarcinoma Treated With Combined Conversion Immunotherapy.

Immune checkpoint inhibitor (ICI)-based combined neoadjuvant/conversion therapy (NAT) is increasingly utilized in the management of initially unresectable intrahepatic cholangiocarcinoma (iCCA). Relia…

Thérapies de Conversion

Chen, W., Sang, Y., Ting, S. o. o. n. . G. S., Jun, C. h. e. n. . E. C., Wu, G., Lin, X., Luo, R., Gao, Q., Zhou, J., Xia, H., Zhu, K., & Shi, R. (2026). Immune Related Pathological Features and Predictive Score in Intrahepatic Cholangiocarcinoma Treated With Combined Conversion Immunotherapy.. Mod Pathol, 101020. https://doi.org/10.1016/j.modpat.2026.101020

09/06/2026 Lire →

Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma.

Systemic therapy for advanced hepatocellular carcinoma (HCC) has evolved from a linear, stepwise algorithm into a multidimensional and truly polyhedral process shaped by treatment response, liver func…

Thérapies de Conversion

Fortuny, M., Chan, L. L., da, F. o. n. s. e. c. a. . L. G., Abou-Alfa, G. K., Chan, S. L., & Reig, M. (2026). Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma.. Hepatology. https://doi.org/10.1097/HEP.0000000000001767

08/06/2026 Lire →

Conversion surgery after immunotherapy and chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology: A retrospective cohort study.

BACKGROUND: The efficacy of conversion therapy for gastric cancer with peritoneal metastasis (P1) and/or positive peritoneal lavage cytology (CY1) treated with immunotherapy remains unclear. This stud…

Thérapies de Conversion

Liang, H., Huang, H., Xie, Q., Huang, K., Li, Z., Zhang, H., Zhong, R., Yan, X., Lai, M., Zhao, L., & Li, G. (2026). Conversion surgery after immunotherapy and chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology: A retrospective cohort study.. Chin Med J (Engl). https://doi.org/10.1097/CM9.0000000000004095

03/06/2026 Lire →

Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008).

Whether progression-free survival (PFS) is a valid surrogate endpoint for overall survival (OS) in patients who underwent conversion therapy for hepatocellular carcinoma (HCC) remains uncertain. The p…

Thérapies de Conversion

Wu, J. W., Yang, D. L., Chen, S. C., Li, M. J., Liang, Y. R., Wang, X. Y., Yao, H. B., Liu, J., Wu, P. S., Peng, N., Nong, J. L., Yu, Y. Q., Ye, L., Su, Z., Qin, C., Chen, K., Yan, Y. H., Zeng, F. J., Liu, S. P., … GUIDANCE, i. n. v. e. s. t. i. g. a. t. o. r. s. (2026). Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008).. Sci Rep. https://doi.org/10.1038/s41598-026-53344-3

03/06/2026 Lire →

Research advances in dual-conversion therapy for hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is a malignant tumour with high global incidence and mortality rates, particularly prevalent in Asia and Africa. Despite advances in diagnostic and therapeutic technique…

Thérapies de Conversion

Shao, J., Han, C., & Peng, T. (2026). Research advances in dual-conversion therapy for hepatocellular carcinoma.. Crit Rev Oncol Hematol, 225, 105404. https://doi.org/10.1016/j.critrevonc.2026.105404

02/06/2026 Lire →